Abstract
The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% ± 14%, P =.04) and the combination group (-46% ± 8%, P =.05) than in the atorvastatin group (-39% ± 11%). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0% ± 5.2% and -0.4% ± 4.0%, P =.03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction.
| Original language | English |
|---|---|
| Pages (from-to) | 167-174 |
| Number of pages | 8 |
| Journal | Journal of Cardiovascular Pharmacology and Therapeutics |
| Volume | 15 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2010 Jun 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
Cite this
}
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. / Her, Ae Young; Kim, Jong Youn; Kang, Seok Min; Choi, Donghoon; Jang, Yangsoo; Chung, Namsik; Manabe, Ichiro; Lee, Sang Hak.
In: Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 15, No. 2, 01.06.2010, p. 167-174.Research output: Contribution to journal › Article
TY - JOUR
T1 - Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism
AU - Her, Ae Young
AU - Kim, Jong Youn
AU - Kang, Seok Min
AU - Choi, Donghoon
AU - Jang, Yangsoo
AU - Chung, Namsik
AU - Manabe, Ichiro
AU - Lee, Sang Hak
PY - 2010/6/1
Y1 - 2010/6/1
N2 - The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% ± 14%, P =.04) and the combination group (-46% ± 8%, P =.05) than in the atorvastatin group (-39% ± 11%). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0% ± 5.2% and -0.4% ± 4.0%, P =.03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction.
AB - The aim of this study was to compare the effects of 3 different statin regimens that have equivalent low-density lipoprotein cholesterol (LDL-C) lowering efficacy on the apolipoprotein B/A1 ratio and glucose metabolism. After a 4-week dietary lead-in, 90 hypercholeserolemic patients were randomly assigned to 1 of 3 treatment groups for 8 weeks: atorvastatin 20 mg, rosuvastatin 10 mg, or atorvastatin/ezetimibe 5 mg/5 mg. At drug treatment week 8, we compared the percentage changes in lipid parameters, apolipoprotein B/A1 ratio, hemoglobin A1c, and homeostasis model assessment-insulin resistance (HOMA-IR) from baseline. Seventy-six patients completed the study and the percentage changes in LDL-C were comparable among the groups. However, the percentage reduction in the apolipoprotein B/A1 ratio was significantly greater in the rosuvastatin group (-47% ± 14%, P =.04) and the combination group (-46% ± 8%, P =.05) than in the atorvastatin group (-39% ± 11%). The percentage increase in hemoglobin A1c was small but significantly greater in the atorvastatin group compared to the combination group (3.0% ± 5.2% and -0.4% ± 4.0%, P =.03). The effect of rosuvastatin on hemoglobin A1c was not different from those of the other 2 regimens. The effects of 3 statin regimens were similar on HOMA-IR. In conclusion, 3 statin regimens have differential effect on apolipoprotein B/A1 and glycemic control after comparable LDL-C reduction.
UR - http://www.scopus.com/inward/record.url?scp=77951887479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951887479&partnerID=8YFLogxK
U2 - 10.1177/1074248409357922
DO - 10.1177/1074248409357922
M3 - Article
C2 - 20147603
AN - SCOPUS:77951887479
VL - 15
SP - 167
EP - 174
JO - Journal of Cardiovascular Pharmacology and Therapeutics
JF - Journal of Cardiovascular Pharmacology and Therapeutics
SN - 1074-2484
IS - 2
ER -